Stockreport

ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate [Yahoo! Finance]

ALX Oncology Holdings Inc.  (ALXO) 
PDF ALX2004, the company's first ADC, was fully designed and developed in-house by ALX Oncology scientists Company expects to initiate Phase 1 clinical trials of ALX2004 [Read more]